Trial Profile
Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Levomilnacipran (Primary)
- Indications Major depressive disorder; Stroke
- Focus Pharmacodynamics
- Sponsors Pierre Fabre
- 27 Oct 2014 New trial record